Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Akebia Therapeutics Q4 Sales $56.200M Beat $55.393M Estimate

Author: Benzinga Newsdesk | March 14, 2024 04:36pm
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $56.200 million which beat the analyst consensus estimate of $55.393 million by 1.46 percent. This is a 1.85 percent increase over sales of $55.180 million the same period last year.

Posted In: AKBA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist